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Clustering of insulin resistance and dysmetabolism with obesity is attributed to pathologic adipose tissue. The morphologic
hallmarks of this pathology are adipocye hypertrophy and heightened inﬂammation. However, it’s underlying molecular
mechanisms remains unknown. Study of gene function in metabolically active tissues like adipose tissue, skeletal muscle and
liveris a promisingstrategy. Microarrayis a powerful technique ofassessmentofgenefunction by measuringtranscriptionoflarge
number of genes in an array. This technique has several potential applications in understanding pathologic adipose tissue. They
are: (1) transcriptomic diﬀerences between various depots of adipose tissue, adipose tissue from obese versus lean individuals,
high insulin resistant versus low insulin resistance, brown versus white adipose tissue, (2) transcriptomic proﬁles of various
stages of adipogenesis, (3) eﬀect of diet, cytokines, adipokines, hormones, environmental toxins and drugs on transcriptomic
proﬁles, (4) inﬂuence of adipokines on transcriptomic proﬁles in skeletal muscle, hepatocyte, adipose tissue etc., and (5) genetics
of gene expression. The microarray evidences of molecular basis of obesity and insulin resistance are presented here. Despite the
limitations,microarray has potential clinical applications in ﬁnding new molecular targets for treatment of insulin resistance and
classiﬁcationof adipose tissue based on future risk of insulin resistance syndrome.
1.Introduction
The term insulin resistance means impairment in insulin
action at its target organs [1]. This biochemical defect is
commonly seen in subjects with visceral obesity, and it
clusters with modern life diseases like type-2 diabetes mel-
litus, hypertension, dylipidemia and atherosclerotic vascular
disease [2–4]. This association was initially demonstrated
in clinical studies, and subsequently epidemiological studies
done across the globe have generated convincing evidences
to support this association [5–8]. Increasing adipose tissue
mass was found to be associated with altered fat metabolism
andinﬂammation,thuscontributingtodiabetesandvascular
disease. This association is recognized clinically as metabolic
syndrome. However, questions have been raised on existence
of metabolic syndrome as a distinct disease because its
pathophysiology is still not well deﬁned [9–13].
Recently, the concept of “adiposopathy” has been, sug-
gested to deﬁne this cluster of obesity, inﬂammation and
metabolic/vascular complications as a formal disease [14–
16]. The basic assumption is that occurrence of diabetes
and other metabolic problems are related to both quantity
and quality of fat and this fat has unique cellular and
molecular pathology. Its precise etiology is unknown but
expected to have a genetic component and is complex,
that is, contributed by both hereditary and environmental
factors [17, 18]. Some racial groups like Pima Indians and
Asian Indians have strong genetic factor in their increased
susceptibility to develop diabetes [19–22]. Identiﬁcation of
this genetic component is pursued intensively and is on
lines of strategy recommended for any complex trait [23–
26]. The cornerstone of this complex genetic trait dissection
is genomewide association of clinical phenotypes as well as
gene function [27]. Microarray is a powerful technique of2 Journal of Obesity
assessment of expression of genes in a tissue at any time at
genomewide scale and has been applied in understanding
role of adipose tissue in insulin resistance [28–31]. The
clinical implications of these microarray evidences and the
insight gained into the understanding adiposopathy are
presented here.
2.Overviewofthe Conceptof
PathologicAdiposeTissue andItsRolein
InsulinResistance
Thehallmark pathologicfeatureofadiposopathyisadipocyte
hypertrophy [32–34] and visceral deposition [35–42]. The
other features are adipose tissue macrophage [43, 44],
possibly lymphocytic inﬁltration [45], poor angiogenesis
[46, 47], intercellular matrix defects [48–50]a n d“ c r o s st a l k ”
that is, fat deposition in other organs like liver, muscle,
pancreatic beta cells, and so forth, [51–53]. Adipose tissue
is not only the largest endocrine organ of the body but has
unique ability to adapt its size in response to calorie excess.
The initial compensation is adipocyte hypertrophy but with
continued fat deposition there is recruitment of committed
mesothelial stem cell progenitors of preadipocytes [54].
Their proliferation leads to formation of small adipocytes
which are metabolically eﬃcient in storing excess fat. This
adipocyte proliferation is called adipogenesis. Impairment
in adipogenesis leads to further adipocyte hypertrophy.
These hypertrophied cells have imbalance in lipid synthesis
(lipogenesis) and breakdown (lipolysis) and overexpress free
f a t t ya c i dﬂ u x .T h i sh e i g h t e n e dF F Aﬂ u xp l a ya ni m p o r t a n t
role in insulin resistance and other metabolic defects of
obesity [55, 56].
Increasing adipose tissue mass has also been found to
be associated with macrophage inﬁltration [57]. It is seen
in both genetic and nutritional animal models of obesity
as well as in human obesity. These macrophages secrete a
large number of cytokines like TNF-α,I L - 1 ,I L - 6 ,a n ds o
forth, [58, 59]. These inﬁltrating macrophages are of two
types M1and M2. The phenotypic switch from M2 to M1
is possibly an important determinant of insulin resistance
[60]. Recently CD11c+ macrophages were found to be the
marker of insulin resistance in human obesity [61]. This
inﬂammatory state of adipose tissue plays an important role
in insulin resistance [62, 63]. Adipocyte hypertrophy itself
was also found to be associated macrophage inﬁltration and
heightened cytokine/adipokine secretion and inﬂammation
[64, 65].
3.Relevanceand PowerofMicroarray:
The EvidencesRequiredto SupportConcept
ofPathologic AdiposeTissue
The term microarray represents an array of large number
of microscopic spots on a solid surface [66, 67]. The solid
surface could be a glass slide or nylon membrane or quartz
wafer. These spots couldbe of complementary cDNA(cDNA
microarray), oligonucleotide probes (high density oligonu-
cleotide microarray), protein (protein array), or microRNA
(microRNA microarray). Presence of a large number of
spots on one slide (which could be of even genomewide
scale for DNA chip) and their ability to hybridize with its
complementary sequence in the target sample with high
precision gives this technology the power of genomewide
study in single experiment. Because of these advantages
this technology is presently the most frequently used tech-
nique for the study complex molecular functions in a cell
[68].
Because DNA microarrays simultaneously measure ex-
pression ofthousandsofgenesina givencellat a givenpoint,
therefore informationgained from thesestudiescangenerate
working hypothesis for molecular pathways essential to a
given biologic process. These transcriptomic proﬁles depend
on the cell type, genotype, and environment of the cell.
Therefore it can be applied for the study of following
aspectsofadiposopathy[69].First,toﬁndthetranscriptomic
diﬀerences between various depotsof adipose tissue, adipose
tissue from obese versus lean individuals, high insulin
resistance versus low insulin resistance, and brown versus
white adipose tissue. Second, to see transcriptomic proﬁles
of various stages of adipogenesis, that is, transcription
control of adipogenesis. Third, to see eﬀect of factors like
diet, cytokines, adipokines, hormones, environmental toxins
and drugs on transcriptomic proﬁles. Fourth, to see the
inﬂuence of adipokines on transcriptomic proﬁles in skeletal
muscle, hepatocyte, adipose tissue, and so forth. Fifth, to
ﬁnd genetics of gene expression, that is, integration of
gene expression phenotypes with genomewide association.
Sixth, the assessment of adipose tissue transcription control
by study of genomewide gene methylation studies and
microRNA by microarray.
The other potential applications of microarray are: study
of gene sequence variation by typing of SNPs and copy
number variation by using SNP arrays.
4.Obesity and Inﬂammation:
The MicroarrayEvidences
Several human and animal model studies have compared
adipose tissue gene expression proﬁles of obese and lean
individuals [31, 70–75]. A large number of genes repre-
senting various molecular functions and pathways were
found to be diﬀerentially expressed in adipose tissue of
obese subject. Most of these genes were found to be in the
molecular pathways of adipose tissue inﬂammation, lipid
and carbohydrate metabolism, adipogenesis and cytoskeletal
structure regulation and so forth. However, the most of the
genes identiﬁed in any studies could not be replicated in
subsequent studies. It could be because of several reasons
like genetic diﬀerences in study population, disease hetero-
geneity, and nonuniform physiologic condition at time of
sampling and method of sampling. But it is important to
note that gene expression proﬁling was found to be altered
with obesity in almost all studies. This suggests that increase
in adipose tissue mass is not merely a quantitative change,
but it also alters its quality, therefore supports the concept of
adiposopathy.Journal of Obesity 3
Increasing adipose tissue mass was found to be asso-
ciated with upregulation of inﬂammation-related genes in
almost all studies [76]. When the stromal-vascular frac-
tion of adipose tissue was separated from adipocytes, the
inﬂammation-related genes were upregulated in stromal
fraction [77, 78]. These ﬁndings suggest that the inﬂam-
matory state of adipose tissue is predominantly because
of inﬁltrating macrophages. These macrophages secrete a
large number of inﬂammatory cytokines like TNF-α,I L - 6 ,
IL-1, and so forth, [58, 59]. In fact microarray evidences
also support the histology ﬁndings of increased macrophage
inﬁltration in adipose tissue in obesity. However it is worth
mentioning here that adipocytes, when cultured isolated
even then showed upregulation of inﬂammation-related
genes. Though the relative contribution of adipocytes in
overall systemic inﬂammation of obesity is much less as
compared with macrophages, but their precise role in
initiation of inﬂammatory seems to be very important.
The current evidences suggest that adipocyte hypertrophy
is associated with increased release of TNF-α,a ni n ﬂ a m -
matory state [79]. These cytokines plays an important
role in lymphocyte and macrophage inﬁltration in the
adipose tissue and further augmentation of inﬂammation by
heightened cytokine release. A vicious cycle is generated as
adipokines released from inﬁltrating macrophages impairs
adipogenesis, and augments free fatty acid/cytokine release
from hypertrophied adipocytes. Diabetics in one study were
found to have not only much higher FFA level and insulin
resistance than BMI-matched controls, but also showed
positive correlation between them [80]. The vicious cycle
of augmented inﬂammation in adipose tissue could be the
underlying mechanism of this ﬁnding.
Some recent studies examined eﬀect of inﬂammatory
factors on adipocytes. Shah et al. [81] applied microarray
mRNA proﬁling of human adipose during endotoxemia to
identify novel inﬂammation-induced adipose tissue genes.
Several genes implicated inﬂammation, but not known to be
expressed in adipose tissue were upregulated in response to
induced inﬂammation. These ﬁndings suggest that induced
inﬂammation further augments inﬂammation of obesity.
Obesity was found to be associated with recruitment of
lymphocytes [82–84] and increased expression of inﬂam-
mation-related genes from M1 macrophages [85–87]. These
inﬁltrating cells play an important role in inﬂammation of
obesity.
Apart from inducing inﬂammation, inﬁltrating macro-
phages also inﬂuence remodeling of adipose tissue. O’Hara
et al. [88] treated human adipocytes in culture with macro-
phage conditioned medium. Microarray analysis identiﬁed
1,088 genes diﬀerentially expressed in response to the
conditioned medium at both 4 and 24h (754 upregulated,
334 downregulated at 24h); these included genes associated
with inﬂammation and macrophage inﬁltration. A cluster
of matrix metalloproteinase genes were highly upregulated
at both time points, including MMP1, MMP3, MMP9,
MMP10, MMP12 and MMP19. At 4 and 24h, MMP1
was the most highly upregulated gene (>2,400-fold increase
in mRNA at 24h). ELISA measurements indicated that
substantial quantities of MMP1 and MMP3 were released
from adipocytes incubated with conditioned medium, with
little release by control adipocytes. Treatment with TNF-
alpha induced substantial increases in MMP1 (>100-fold)
and MMP3 (27-fold) mRNA level as well as MMP1 and
MMP3 release in adipocytes, suggesting that this cytokine
could contribute to the stimulation of MMP expression by
macrophages, thus contributing to tissue remodeling during
adipose tissue expansion in obesity.
Though there are convincing evidences for the role of
macrophages in adipose tissue inﬂammation, the precise
cause of their inﬁltration in th ea d i p o s et i s s u ei ss t i l ln o t
known. However several hypotheses have been suggested.
They are as follow (1) increasing adipose tissue mass not
accompanied by increase in its vascularity leads to local
hypoxia, which is the cause of macrophage inﬁltration [89–
92], (2) obesity is associated with increased expression of
chemokines like monocyte chemoattractant protein (MCP)-
1, MCP-3, macrophage inﬂammatory protein (MIP)-1α,a n d
they play an important role in macrophage inﬁltration [93–
97] (3) increasing adiposity is associated with elevated leptin
levels and later increases adhesion molecule expression in
endothelialcellsandmonocytediapedesis[98,99],and(4)as
adipocytes share several characters with immune cells, it has
alsobeensuggestedthatpreadipocytesaretransdiﬀerentiated
into macrophages [98].
There is also possible role of epigenetic factors in adipose
tissue inﬂammation. Epigenetic modiﬁcations are chemical
additions to DNA and histones that are associated with
changes in gene expression and are heritable but do not alter
the primary DNA sequence. DNA methylation is one of the
epigenetic modiﬁcation and in mammals may be associated
with gene silencing. The role of epigenetic factors in inﬂam-
mation of obesity was suggested in transgenic mice overex-
pressing DNAmethyltransferase (Dnmt3a). Gene expression
levels of inﬂammatory cytokines such as tumor necrosis
factor-alpha (TNF-alpha) and monocyte chemoattractant
protein-1 (MCP-1) were higher in Dnmt3a mice than in
wild-type mice on a high-fat diet. This study suggests that
increased expression of Dnmt3a in the adipose tissue may
contribute to obesity-related inﬂammation. However there
are no human studies to support these ﬁndings [100].
5.Adipogenesis Defects in Pathologic Adipose
Tissue:The RoleofTranscriptionalFactors
The pathologichallmark ofadiposopathy isadipocytehyper-
trophy and has been hypothesized to be due to defects in
proliferation and diﬀerentiation of mesenchymal stem cells
and preadipocytes into mature adipocytes, a process called
adipogenesis [101]. Adipogenesis is a complicated process
and had been extensively studied. Much progress has been
made in the last two decades in deﬁning transcriptional
events controlling the diﬀerentiation of mesenchymal stem
cells into adipocytes. A complex network of transcription
factors and cell-cycle regulators, in concert with speciﬁc
transcriptional coactivators and corepressors, respond to
extracellular stimuli to activate or repress adipocyte diﬀeren-
tiation [102]. PPAR-γ and C/EBP-α are the major regulatory4 Journal of Obesity
factors. Precise understanding of this process is expected
to open avenues for discovery of new molecular targets for
prevention of expansion of adipose tissue in obesity and its
transformation from benign to pathologic tissue found in
high insulin resistance conditions.
Microarray is one of the most powerful techniques for
understanding the process of adipogenesis not only because
of its ability to study molecular function at large scale
in single experiment, but also because of its precision,
sensitivity and speciﬁcity. Therefore, gene expression during
various stages of adipogenesis has been extensively studied
and the data so generated has been subjected to meta-
analysis. There are more than 20 published reports on gene
expression proﬁling during various stages of adipogenesis
[103–125]. Most of these studies used diﬀerent platforms
and had inherent problemslikediﬀerentprobes, annotations
and probe sequences. Apart from the heterogeneity of
platforms these studies also had heterogeneity in terms of
model studied: in vitro murine cell lines in culture, animal
models and human mesenchymal stem cell/preadipocyte in
vitro culture models. However, an exhaustive analysis and
comparison of commonly used microarray platforms by
a multicenter consortium (MAQC) showed—contrary to
earlier reports [126, 127]—acceptable concordance between
the platforms [128]; however, there is a necessity for careful
controlofbiologicalsamplesandcloseadherencetostandard
protocols.
A large number of genes identiﬁed by these microarray
studies were found to be associated with adipocyte develop-
ment. Some of them were further studied from point of view
of understanding molecular mechanisms of adipogenesis.
Few of them are as follows: ﬁrstly, several members of
the Kr¨ uppel-like factor family have been implicated in
adipogenesis [129]. In microarray studies, Klf4 was shown
to function as an immediate early regulator of adipogenesis
by inducing C/EBP-β and is required for adipogenesis
[129]. Klf6, Klf15 and Klf5 have been found to play a role
in adipogenesis. Klf5 acts by transactivating PPAR-γ.T h e
available evidences suggest that these factors function by
recruiting diﬀerent coactivators or repressors [102]. Sec-
ondly, microarray studies identiﬁed diﬀerential expression
of zinc ﬁnger containing transcription factor Egr2 (Krox20)
during adipogenesis. The expression of Egr2 is activated
very early after induction of adipogenesis. It stimulates
adipogenesis at least in part through activating C/EBP-β by
binding to its promoter [130]. Thirdly, expression proﬁles
of adipogenesis have identiﬁed orphan nuclear receptor
Nr4a1 (Nur77) as an early gene. But, there are conﬂicting
reports on eﬀects of its altered expression in adipogenesis
[131–133]. Another nuclear hormone receptor involved in
adipogenesis is Nr1h3 (LXRalpha). A broader role of Nr1h3
in regulation of metabolism in adipocytes was suggested
and the eﬀects of Wnt-signaling in adipocyte diﬀerentiation
were studied in timed series microarray experiments of 3T3-
L1 cells and retroviral infected 3T3-L1 cells encoding Wnt1
[134]. It is known that liver X receptors (LXRs) regulate
cholesterol and fatty acid metabolism in liver tissue and
macrophages. Recently it was also shown that activated
Nr1h3stimulateadipocytediﬀerentiationthrough induction
of PPAR-γ expression, but it is not required for adipocyte
diﬀerentiation [135]. A nuclear receptor gene expression
atlas during the diﬀerentiation of 3T3-L1 cells, assessed
using qPCR, also showed the importance of other nuclear
receptors such as the Nr2f2 (COUP-TF2) in adipogenesis
[124]. Fourthly, the role of Ebf1 (O/E-1), a helix-loop
helix transcription factor, was studied in adipocytes with
microarray analysis of Ebf1 overexpression in NIH-3T3 cells
[115]. Further experiments helped place Ebf1 within the
known transcriptional cascade of adipogenesis [136]. By
the year 2000, it was shown that Gata2 and Gata3 are
speciﬁcally expressed inadipocyteprecursorsand theirdown
regulation sets the stage for terminal diﬀerentiation [137].
This type of expression proﬁle could be conﬁrmed later
on with microarray experiments. A role for transcriptional
coregulators in the control of energy homeostasis could be
shown by knockout of the corepressor Nrip1 (RIP140) in
adipocytes [117].
Microarray studies have also identiﬁed a number of
enzymes regulating adipogenesis. For example, Xanthine
dehydrogenase(Xdh,XOR),Stearoyl-CoAdesaturase(Scd1),
adipose triglyceride lipase Pnpla2 (ATGL), and so forth.
Apartfromidentiﬁcationofvarioustranscriptionfactorsand
genes showing diﬀerential expression during adipogenesis,
the other applications of microarray in understanding this
process are: (1) understanding the regulation of expression
of various genes, (2) inﬂuence of perturbation of these genes
on adipocyte physiology, and (3) eﬀects of various drugs,
nutrients and so forth.
Methylation of cytosine and formation of 5-methyl-
cytosine are the only covalent DNA modiﬁcation known
in vertebrates [138]. This epigenetic modiﬁcation regulates
gene expression. Horri et al. recently studied role of DNA
methylation in control of insulin-induced adipogenesis in
3T3-L1 preadipocytes using a method called microarray-
based integrated analysis of methylation by isoschizomers
(MIAMI). The MIAMI revealed that Hpa II sites of exon 1 in
a Rho guanine nucleotide exchange factor 19 (ARHGEF19;
WGEF) gene were demethylated during adipocyte diﬀerenti-
ation of 3T3-L1 cells. This study suggests that adipogenesis
was regulated by WGEF expression through DNA methyla-
tion change [139]. However, Ocada et al have shown that the
diet-induced upregulation of leptin, Mest/Peg1, and sFRP5
geneexpressioninWATduringthedevelopmentofobesityin
miceisnotmediateddirectlybychangesinDNAmethylation
[140].
MicroRNAs (miRNAs) are short noncoding RNA that
posttranscriptionally regulates gene expression. Some miR-
NAs have been proposed to be associated with obesity.
Nakanishi et al. [141] found the upregulation of miR-335 in
obesity using microarray analysis for miRNA. Furthermore,
miR-335 levels were closely correlated with expression levels
of adipocyte diﬀerentiation markers such as PPARgamma,
aP2, and FAS in 3T3-L1 adipocyte. These ﬁndings provide
the ﬁrst evidence that the upregulated expressions of miR-
335 in liver and WAT of obese mice might contribute to the
pathophysiology of obesity. Sun et al. [142]a l s oi n v e s t i g a t e d
whether micro RNA plays a role in adipogenesis. They
performed microarray analysis to detect miRNA expressionJournal of Obesity 5
during 3T3-L1 preadipocyte diﬀerentiation. Several miR-
NAs,includinglet-7,were upregulatedduring 3T3-L1adipo-
genesis.Ectopicintroduction oflet-7into3T3-L1cellsinhib-
ited clonal expansion as well as terminal diﬀerentiation. The
mRNAencodinghigh-mobility groupAT-hook 2(HMGA2),
a transcription factor that regulates growth and proliferation
in other contexts, was inversely correlated with let-7 levels
during 3T3-L1 cell adipogenesis, and let-7 markedly reduced
HMGA2 concentrations. Knockdown of HMGA2 inhibited
3T3-L1 diﬀerentiation. These results suggest that let-7 plays
an important role in adipocyte diﬀerentiation and that it
does so in part by targeting HMGA2, thereby regulating the
transition from clonal expansion to terminal diﬀerentiation.
6.Mechanism of Inﬂammationand HighFFA
FluxfromHypertrophiedAdipocytes
Adipose tissue is the major energy reservoir of the body. The
excess calories resulting from energy imbalance are predom-
inantly stored as triglycerides. About 95% of adipocyte mass
consistsoftriglycerides.Fatcontentofan adipocyte(inother
words size of an adipocyte) depends on balance between
fat deposition (by either nutrient transport or fat synthesis
by lipogenesis) and fat depletion (by either utilization in
lipolysis or export out of cell). However this single cell fat
b a l a n c em u s tb ed i ﬀerentiated from overall fat balance of
the body, which in addition also depends on recruitment
of newer adipocytes by adipogenesis. When the process of
adipogenesis is insuﬃcient size of an individual fat cell
increases to accommodate excess calories deposited as lipids.
The lipid deposition in an adipocyte is regulated by the
nutrients, hormones and perilipin family of lipid droplet
coat proteins [143]. The process of lipogenesis is stimulated
by excess of carbohydrates and inhibited by polyunsaturated
fatty acids and fasting. It is hormonally regulated, stimulated
by insulin and inhibited by growth hormone and leptin.
SREB-1 and PPAR-γ are the major transcriptional regulators
of this process and mediate the action of nutrients and
hormones [144]. The process of lipolysis is stimulated by
fasting, catecholamines, and atrial natriuretic peptide and
inhibited by insulin. It is mediated by hormone sensitive
lipase (HSL) and adipose triglyceride lipase (ATGL).
The mechanism of adipose tissue lipid balance has been
extensively studied from point of view of understanding
molecular basis of obesity, inﬂammation and high free
fatty acid ﬂux. Microarray has potential application of
identifying molecular pathways underlying physiology of
lipid balance of an adipocyte in health and disease. It is
also of help in understanding eﬀects of various nutrients,
chemical, experimental drugs on fat storage and lipolysis by
an adipocyte.
Gene expression proﬁling using microarray has been
applied in understanding diﬀerences between small and
hypertrophied adipocytes. Jernas et al. [145]c o m p a r e dg e n e
expression proﬁles of hypertrophied adipocytes with smaller
adipocytes obtained from the same individual. 14 genes
showed 4-fold upregulation in hypertrophied adipocytes.
Five of them were immune related: E-selectin, interleukin
(IL)-8, serum amyloid a (SAA), C1q receptor 1, and CXCL2
also known as MIP-2 or macrophage inﬂammatory protein-
2.SAAissecretedbyadiposetissueandisacutephaseprotein
implicated in insulin resistance, adipose tissue macrophage
inﬁltration, and cholesterol reverse transport [146–148].
Therefore, SSA and other proteins could be important
mediators of hypertrophied adipocyte in insulin resistance,
inﬂammation, and diabetes. TM4SF1 gene was also upregu-
lated in hypertrophied adipocytes. The precise function of
this protein is not known, but speculated to be related to
inﬂammation [149]. This gene was also over-expressed in
visceral adipose tissue as well as among obese individuals
[150]. It was mapped to the chromosomal region which was
also found to be linked with BMI and fasting insulin level
among Pima Indians [151]. Therefore these transcriptomic
ﬁndings support the concept that hypertrophied adipocyte
itself induces inﬂammatory changes in adipose tissue.
Hypertrophied adipocytes also releases large amount of
saturated fatty acids. These saturated free fatty acids act as
natural ligands for toll-like receptor 4 and activate inﬂam-
mation in both adipocytes and inﬁltrating macrophages
via nuclear factor kappa B (NF-κB) [152]. In a recent
study cDNA microarray analysis of saturated fatty-acid-
stimulated macrophages in vitro and obese adipose tissue
in vivo was done by the same group of investigators. They
ﬁnd activating transcription factor (ATF) 3 (amember ofthe
ATF/cAMPresponse element-bindingproteinfamily ofbasic
leucine zipper-type transcription factors) as a target gene of
saturatedfattyacids/TLR4signalingin macrophagesinobese
adipose tissue. Importantly, ATF3, when induced by satu-
rated fattyacids, can transcriptionally repress tumor necrosis
factor-α productionin macrophagesin vitro. Overexpression
of ATF3 speciﬁcally in macrophages results in the marked
attenuation of proinﬂammatory M1 macrophage activation
in the adipose tissue. Therefore it is hypothesized that it
could be a negative feedback mechanism that attenuates
obesity-induced macrophage activation. Hence activation of
ATF3 in macrophages oﬀers a novel therapeutic strategy to
preventortreatobesity-inducedadipos etis s ueinﬂammation
[153].
Some of the recent microarray studies have examined
eﬀectsof some chemicals on process oflipogenesis and lipol-
ysis. Dietary ﬂavonoid phloretin enhances 3T3-L1 adipocyte
diﬀerentiation and adiponectin expression at least in part
through PPAR-γ activation [154]. In a recent microarray
study it was shown that phloretin positively regulates the
expression of numerous genes involved in lipogenesis and
triglyceride storage, including GLUT4, ACSL1, PEPCK1,
lipin-1 and perilipin (more than twofold). The expres-
sion of several genes encoding adipokines, in addition to
adiponectin and its receptor, was positively or negatively
regulated in a way that suggests a possible reduction in
systemic insulin resistance and obesity-associated inﬂamma-
tion. Improvement of insulin sensitivity was also suggested
by the overexpression of genes associated with insulin
signal transduction, such as CAP, PDK1 and Akt2. Many
of these genes are PPARgamma targets, conﬁrming the
involvement ofPPARgamma pathway in the phloretin eﬀects
on adipocytes [155].6 Journal of Obesity
Docosahexaenoic acid (DHA) increases lipolysis and
decreaseslipogenesis. Wang et al. [156] treated human breast
adipocyteswithhSAA1(recombinanthumanserumamyloid
Ap r o t e i n )o rD H Ain vitro. They ﬁnd that expression of
peroxisome proliferator-activated receptor gamma and other
lipogenic genes was decreased, whereas the expression of
several lipolytic genes was increased. Glycerol release was
increased by both SAA and DHA treatments, suggesting that
they increased lipolytic activity in human adipocytes. The
expression of perilipin, a lipid droplet-protective protein,
was decreased, and hormone-sensitive lipase was increased
by both of hSAA1 and DHA treatment. They speculated
that the mechanism of lipolysis by DHA or SAA is at least
partially the result of increased expression of hormone-
sensitive lipase and decreased expression of perilipin. The
ﬁnding of this study also suggested that as DHA treatment
increased expression of hSAA1 in human adipocytes, the
DHA-mediated reduction in expression of lipogenesis genes
and enhancement of lipolysis may be through the activity of
hSAA1.
7.SkeletalMuscleandHepatocyte
TranscriptomeinInsulin-ResistantStates:
Role of Cytokines and FFA
Obesity and insulin resistance is associated with fatty liver
disease manifested clinically as increased triglyceride deposi-
tion in liver (steatosis) and progressive necroinﬂammatory
liver disease (steatohepatitis, NASH) [157, 158]. Increased
FFA ﬂux from adipose tissue in insulin-resistant state is asso-
ciated with hepatic fat deposition, impairment in mitochon-
drial energy biogenesis and insulin resistance. It was recently
suggested that rather than being an “innocent bystander”,
liver steatosis may be the “guilty party” of the progression
to cirrhosis [159–161] and possibly in the development of
hepatocellular carcinoma (HCC) [162]. This can result in
end-stage liver disease requiring liver transplantation [163–
165]. Therefore, understanding the molecular mechanisms
underlying FLD is of major importance. Microarray has
potential application in understanding molecular basis of
fatty liver disease.
Chiappini et al. [166] studied global gene expression
in human liver steatosis. They ﬁnd that mitochondrial
alterations play a major role in the development of steatosis.
Activation of inﬂammatory pathways is present at a very
early stage of steatosis, even if no morphological sign of
inﬂammation is observed.
Sreekumar et al. [167] compared genomewide transcrip-
tion proﬁles in liver biopsies from cirrhotic stage of NASH
with cirrhosis caused by hepatitis C and healthy controls.
Sixteen genes were uniquely diﬀerentially expressed (4 over-
expressed and 12 underexpressed) in patients with cirrhotic-
stage NASH. Genes that were signiﬁcantly underexpressed
included genes important for maintaining mitochondrial
function (copper/zinc superoxide dismutase, aldehyde oxi-
dase, and catalase). Glucose 6-phospatase, alcohol dehy-
drogenase, elongation factor-TU, methylglutaryl coenzyme
A (CoA), acyl CoA synthetase, oxoacyl CoA thiolase, and
ubiquitin also were underexpressed in NASH. Genes that
were overexpressed in NASH included complement compo-
nent C3 and hepatocyte-derived ﬁbrinogen-related protein,
potentially contributing to impaired insulin sensitivity. In
conclusion, these studies provide evidence for a transcrip-
tionalorpretranscriptional basis for impaired mitochondrial
function (attenuated capacity for the dismutation of reactive
oxygenspecies) and diminished insulin sensitivity (increased
acutephasereactants) inpatientswith histologicallyprogres-
sive NASH.
Cheunget al.[168] studieddiﬀerentiallyexpressed micro
RNAs, their target in NASH and impact of one speciﬁc
diﬀerentially expressed microRNA, miR122. Total of 23
microRNAs were underexpressed or overexpressed. The
predicted targetsofthese microRNAsare known toaﬀect cell
proliferation, protein translation, apoptosis, inﬂammation,
oxidative stress, and metabolism. Underexpression of miR-
122 potentially contributes to altered lipid metabolism
implicated in the pathogenesis of NASH.
Type-2 diabetes is associated with muscle insulin resis-
tance and ﬁrst-degree relativesofthemalso have high insulin
resistance. There is increasing evidence for a link between
insulin resistance and impaired mitochondrial oxidative
phosphorylation (OXPHOS) in human skeletal muscle in
vivo [169–173]. Several microarray-based studies of skele-
tal muscle have reported coordinated downregulation of
OXPHOS genes (mitochondrial biogenesis) in patients with
type 2 diabetes and high-risk individuals [174–177], that
reduced expression of the genes encoding transcriptional
coactivator peroxisome proliferator-activated receptor γ
coactivator 1α (PGC-1α) and nuclear respiratory factor 1
(NRF1)could playa keyrole in these transcriptional changes
[175–177].
However, it is an important question one need to answer
is whether, skeletal muscle insulin resistance is a primary
genetic defect or secondary to high FFA ﬂux and cytokines
secreted from visceral adipose tissue. Frederiksen et al.
[178] generated transcriptional proﬁling of myotubes from
patients with type 2 diabetes mellitus and obese control sub-
jects. They ﬁnd that no single gene was diﬀerently expressed
after correction for multiple testing, and no biological
pathway was diﬀerentially expressed using global pathway
analysis. Inparticular, theyfoundno evidencefordiﬀerential
expression of genes involved in mitochondrial oxidative
metabolism. Consistently, there was no diﬀerence in mRNA
levels of genes known to mediate the transcriptional control
of mitochondrial biogenesis (PPARGC1A and NRF1) or in
mitochondrial mass between diabetic and control myotubes.
Hence the results of this study support the hypothesis
that impaired mitochondrial biogenesis is not a primary
defect in the sequence of events leading to insulin resistance
and type 2 diabetes. The other meaning of this study
is that impaired mitochondrial oxidative phosphorylation
(OXPHOS) in skeletal muscle is possibly reversible with
control of hyperglycemia and dysmetabolism. Sreekumar et
al.[174]studiedgeneexpressionproﬁleintheskeletalmuscle
of patients with type 2 diabetes while not on treatment for
2 weeks and after 10 days of intensive insulin treatment. Of
6,451 genes surveyed, transcriptional patterns of 85 genesJournal of Obesity 7
showed alterations in the diabetic patients after withdrawal
of treatment, when compared with patterns in the nondia-
betic control subjects. Insulin treatment reduced the diﬀer-
ence in patterns between diabetic and nondiabetic control
subjects (improved) in all but 11 gene transcripts, which
included genes involved in structural and contractile func-
tions: growth and tissue development, stress response, and
energy metabolism. These improved transcripts included
genes involved in insulin signaling, transcription factors,
andmitochondrial maintenance. However,insulin treatment
altered the transcription of 29 additional genes involved
in signal transduction; structural and contractile functions;
growth and tissue development; protein, fat, and energy
metabolism. Therefore they identiﬁed several candidate
genesplayingroleinmuscleinsulin resistance, complications
associated with poor glycemic control, and eﬀects of insulin
treatment in people with type 2 diabetes.
Yang et al. [179] compared muscle transcription proﬁles
of equally obese high- and low-insulin-resistant individuals.
The authorsconcludedthat 185diﬀerentiallyexpressed tran-
scripts, 20 per cent were true positives and some could gen-
eratenewhypothesesabouttheaetiologyorpathophysiology
of insulin-resistance. Furthermore, diﬀerentially expressed
genes in chromosomal regions with linkage to diabetes and
insulin-resistance serve as new diabetes susceptible genes.
Nguyen et al. performed gene expression proﬁling on
skeletal muscle of insulin-resistant and insulin-sensitive sub-
jects using microarrays. Microarray analysis of 19,000 genes
in skeletal muscle did not display a signiﬁcant diﬀerence
between insulin-resistant and insulin sensitive muscle. This
was conﬁrmed with real-time PCR. These results suggest
that insulin resistance is not reﬂected by changes in the gene
expression proﬁle in skeletal muscle [180].
8.EffectofCaloricRestriction,
Drugs,and ChemicalToxinsonAdipose
TissueTranscriptome
There are several reports in the literature studying the eﬀect
ofvariousfactorssuchasnutrition,stress, anddrugs,ongene
expression proﬁle ofadipose tissue in animal models, in vitro
cell lines and occasionally in human beings.
Dahlman et al. [181]i n v e s t i g a t e dt h ee ﬀect of diﬀerent
low-energydietsongeneexpressioninhumanadiposetissue.
They ﬁnd that macronutrients have a secondary role in
changes in adipocyte gene expression after energy-restricted
diets. The most striking alteration after energy restriction is
a coordinated reductionin theexpression ofgenesregulating
the production of polyunsaturated fatty acids.
Capel et al. [182] studied eﬀect of calorie restriction,
weight stabilization on insulin sensitivity, and subcutaneous
adipose tissue gene expression proﬁle.They ﬁnd that adipose
tissue macrophages and adipocytes show distinct patterns
of gene regulation and association with insulin sensitivity
d u r i n gt h ev a r i o u sp h a s e so fad i e t a r yw e i g h tl o s sp r o g r a m .
They concluded that macrophage and fat cell gene expres-
sions in adipose tissue are diﬀerentially regulated during
the calorie restriction and weight maintenance phases of
a weight loss program. The diet-induced improvement of
insulin sensitivity is associated with changes in clusters of
genes rather than in single genes, with the sets of genes
being diﬀerent in each phase of the program. The kinetics of
changes within adipose tissue and the interactions between
t h em e t a b o l i cs t a t eo fa d i p o c y t e sa n dt h ea c t i v a t i o ns t a t e
of macrophages appear critical for the understanding of
the beneﬁcial eﬀects on health resulting from a long-term
dietary weight loss program in obese subjects. Cl´ ement et
al. [183] studied changes in subcutaneous adipose tissue
gene expression proﬁles after feeding with very low calorie
diet for 28 days. They ﬁnd that weight loss improves
the inﬂammatory proﬁle of obese subjects through a
decrease of proinﬂammatory factors and an increase of anti-
inﬂammatory molecules. The genes are expressed mostly
in the stromavascular fraction of adipose tissue, which is
shown to contain numerous macrophages. The beneﬁcial
eﬀect of weight loss on obesity-related complications may
be associated with the modiﬁcation of the inﬂammatory
proﬁle in adipose tissue. Viguerie et al. [184] determined
the levels of transcripts for 38 genes that are expressed in
adipose tissue and encode transcription factors, enzymes,
transporters and receptors known to play critical roles in the
regulation of adipogenesis, mitochondrial respiration, lipid,
and carbohydrate metabolism in two groups of 25 obese
subjects following 10-week hypocaloric diet programmes
with either 20–25 or 40–45% of total energy derived from
fat being investigated. Levels of mRNA were measured by
performing real-time RT-PCR on subcutaneous fat samples
obtained from the subjects before and after the diets. Ten
genes were regulated by energy restriction; however, none
of the genes showed a signiﬁcantly diﬀerent response to the
diets. Levels of peroxisome proliferator-activated receptor
gamma coactivator 1alpha mRNA were increased, while
the expression of the genes encoding leptin, osteonectin,
phosphodiesterase 3B, hormone-sensitive lipase, receptor A
for natriuretic peptide, fatty acid translocase, lipoprotein
lipase, uncoupling protein 2 and peroxisome proliferator-
activated receptor gamma was decreased. In accordance with
the comparable loss of fat mass produced by the two diets,
this study shows that energy restriction and/or weight loss
rather than the ratio of fat: carbohydrate in a low-energy
diet is of importance in modifying the expression of genes in
the human adipose tissue. Kolehmainen et al. [185]ﬁ n dt h a t
weight reduction in subjects with metabolic syndrome was
associated with strong down regulation of genes regulating
extracellular matrix and cell death.
van Dijk et al. [186]i n v e s t i g a t e dt h ee ﬀect of a satu-
rated fatty acid-(SFA-) and a monounsaturated fatty acid-
(MUFA-) rich diet on insulin sensitivity, serum lipids, and
gene expression proﬁles of adipose tissue in subjects at
risk of metabolic syndrome. They ﬁnd that consumption
of an SFA diet resulted in a proinﬂammatory “obesity-
linked” gene expression proﬁle, whereas consumption of
a MUFA diet caused a more anti-inﬂammatory proﬁle.
This suggests that replacement of dietary SFA with MUFA
could prevent adipose tissue inﬂammation and may reduce
the risk of inﬂammation-related diseases such as metabolic
syndrome.8 Journal of Obesity
Dietary supplementation of arginine is the physiologic
precursor of nitric oxide (NO), and its dietary supplemen-
tation has potential to reduce the fat mass. Fu et al. [187]
studied eﬀect of arginine supplementation on fat mass and
underlying molecular mechanisms in Zucker diabetic fatty
(ZDF) rat, a genetically obese animal model of type II
diabetes mellitus. They ﬁnd that arginine supplementation
increased adipose tissue expression of key genes respon-
sible for fatty acid and glucose oxidation: NO synthase-
1 (145%), heme oxygenase-3 (789%), AMP-activated pro-
tein kinase (123%), and peroxisome proliferator-activated
receptor gamma coactivator-1alpha (500%). Their ﬁndings
suggest that arginine treatment may provide a potentially
novel and useful means to enhance NO synthesis and reduce
fat mass in obese subjects with type II diabetes mellitus.
Arginine treatment may provide a potentially novel and
useful means to enhance NO synthesis and reduce fat mass
in obese subjects with type-II diabetes mellitus. Another
s t u d yb yJ o b g e ne ta l .[ 188] also showed that high fat diet
and arginine supplementation diﬀerentially regulate gene
expression to aﬀect energy-substrate oxidation, redox state,
fat accretion, and adipocyte diﬀerentiation in adipose tissue.
Their ﬁndings provide a molecular mechanism to explain
a beneﬁcial eﬀect of arginine on ameliorating diet-induced
obesity in mammals.
Molecular mechanisms underlying metabolic eﬀects of
nutritional factors like calorie, fat, arginine, vitamin C,
grape anthocyanins and so forth, were understood in human
beings and animal models. There are isolated reports about
the eﬀects of several factors like stress, dihydrotestosterone,
lipocalin 2, rosiglitazone, licorice ﬂavonoids, Turmeric oleo-
resin, coca, topiramate, leptin, β-adrenoceptor agonists, and
so forth, in animal models, cell lines and occasionally in
humans [189–193].
9.MolecularBasis of Differences
betweenVisceralandSubcutaneousFat:
TranscriptionalEvidences
Association of visceral obesity with increased expression
of cytokines/adipokines and hormones mediating insulin
resistance suggest that these two depots of fat are not
mere diﬀerent locations of same tissue, rather biologically
diﬀerent organs with diﬀerent molecular functions. It is also
possible that they diﬀer in their origin during embryonic life
[194]. Microarray is an important and appropriate tool for
studying diﬀerences in gene function between visceral and
subcutaneous adipose tissue. Several studies have compared
transcriptomes of these two tissues. Ramis et al. [195]
compared transcriptomes of visceral and subcutaneous
tissues and reconﬁrmed by RT-PCR diﬀerential expression
of the two best candidates, carboxypeptidase E (CPE), and
thrombospondin-1 (THBS1) (EST N72406). They ﬁnd that
both genes appeared to be strongly diﬀerentially expressed,
having a higher expression in the visceral depot than in
the subcutaneous. For THBS1, the diﬀerence in expression
between the depots was greater in women than in men.
The involvement of CPE and THBS1 in obesity suggests
that the physiological processes controlled by these genes
contribute to depot and gender-related diﬀerences in the
metabolic complications of obesity. Dolinkov´ ae ta l .[ 196]
evaluated expression proﬁle of genes potentially related to
metabolic complications of obesity in the whole adipose
tissue and isolated adipocytes from subcutaneous (SAT)
and visceral adipose tissue (VAT) from 12 nondiabetic
obese women and 12 lean women. They found increased
expression ofspeciﬁcproinﬂammatory andadipogenicgenes
and reduced expression of speciﬁc lipogenic and insulin
signaling pathway genes in obese relative to lean women
with no preferable localization in SAT or VAT depot. The
geneexpressionsigniﬁcantlydiﬀeredbetweenadipocytesand
adipose tissue but both contributed to the proinﬂammatory
proﬁle in obesity. They conclude that both SAT and VAT
exhibit alterations inthe expression of speciﬁc genespossibly
contributing to proinﬂammatory and insulin resistance state
and consequently to metabolic complications of obesity.
10.GeneticsofGene Expression:
Integrationof Gene Expression,Genotype,
and ClinicalPhenotype
Currently there are two major genomic strategies for iden-
tiﬁcation of genes underlying complex diseases. The ﬁrst
strategy is ﬁnding the gene sequence variants associated with
clinical phenotype [197]. Genomewide association studies
using genomewide SNP markers with diabetes and related
phenotypes have been quite successful in identiﬁcation of
genomic regions having diabetes susceptibility genes [198].
However, limitations of these studies do not provide any
information about function of these genes and the mecha-
nisms involved in pathogenesis of disease. The other strategy
is identiﬁcation of network of coexpressed genes perturbed
in the insulin-resistant state by gene expression proﬁling.
However, gene expression proﬁling does not provide any
information on drivers of disease, and causal information.
Association studies of gene expression phenotypes identify
gene sequence variants regulating gene function and when
combined with clinical information could infer causal asso-
ciationbetweenexpressionanddiseasetrait[199].Identiﬁca-
tionofgenenetworksthatareperturbedbysusceptibilityloci
for a given clinical trait could reﬁne deﬁnition of the trait,
identify disease subtypes,constructgenenetworks associated
withthediseaseandidentifykeydriversofdisease[200–205].
Data on this type of investigations in human adiposopathy is
lacking. However, in segregating mouse population resulted
in the identiﬁcation of a macrophage-enriched network
supported as having a causal relationship with disease traits
associated with metabolic syndrome [206].
11.ClinicalApplications
There are several potential applications of gene expression
proﬁling in clinical practice like ﬁnding the new molecular
targetsofdrugdevelopmentbasedonmolecularmechanisms
underlying insulin resistance, classiﬁcation of insulin resis-
tance into subtypes, molecular diagnostic markers of futureJournal of Obesity 9
insulin resistance in early life, and prediction of therapeutic
response or adverse eﬀects on the basis of transcription
proﬁles [207–209]. At present gene expression proﬁling has
not percolated to clinical practice and is only a research tool.
Several molecular mechanisms identiﬁed by microarray like
those underlying adipogenesis and inﬂammation mediated
by adipose tissue macrophage inﬁltration have potential to
serve new molecular target of drug discovery. PPAR-γ and
i t sa g o n i s t sa r eb e s te x a m p l eo ft h i sc l i n i c a la p p l i c a t i o n .
Similarly, Integration of molecular proﬁling with genotype
and clinical traits and identiﬁcation of DNA polymorphs
which are drivers of insulin resistance associated transcrip-
tion proﬁles has potential application in classiﬁcation of
adiposity into pathogenic and benign fat [210]. More drastic
life-style modiﬁcation and drug therapy to prevent insulin
resistance will be advised in individuals having pathologic
adipose tissue even before they gain weight and develop
insulin resistance.
12.LimitationsofMicroarray
Despite power (i.e., genomewide scale) and multiple appli-
cationsin understanding molecular functions of cell (levelof
gene and protein expression, genomewide association with
SNP markers and copy number variants, RNA splicing, gene
methylation, microRNA study, etc.) there are limitations
of microarray in understanding molecular basis of insulin
resistance. These limitations are both of microarray tech-
nology itself and its application in understanding insulin
resistance.
In contrast to gene sequence, transcriptome depends on
cell type and its environmental conditions; therefore large
amount of data is generated which is analyzed by diﬀerent
methods. Also there is no standardized unit of estimation of
gene expression; hence data is only presented as fold change.
There are no known uniform standard geneexpression levels
for every cell in the body underphysiologic conditions, so
that true assessment of gene expression in pathophysiologic
conditions is impossible [211]. More overdata generated
by using diﬀerent platforms, arrays, and methods of nor-
malization has produced inconsistent data for same type
of experiment performed in diﬀerent labs [128, 212, 213].
Most of the genes prioritized to be diﬀerentially expressed
in adipose tissue, muscle tissue, and so forth, in any study
were not replicated in subsequent study. Lastly molecular
functions identiﬁed by transcriptomic proﬁle could not be
reconﬁrmed by other methods [213].
In addition to limitations of microarray technology
itself, there are many more constrains in its application
in understanding molecular functions of muscle, liver, and
adipose tissue in insulin resistance. Insulin resistance is
a continuous parameter and clinically identiﬁed on crite-
ria which have no pathophysiologic basis (i.e., metabolic
syndrome). Precise labeling of insulin resistance and its
true control is diﬃcult because it is function of adipose
tissue mass and location (visceral or subcutaneous) and
quality (good or bad fat). Moreover transciptome also
depends on the associated conditions like infection, stress,
hyperglycemia, and several drugs used to treat clinical
conditions like diabetes (metformin, glitazones, telmisar-
tan, etc.). The method of obtaining tissue also inﬂuences
gene expression (needle versus open adipose tissue biopsy)
[214].
13.Conclusion
Despite several limitations microarray has proved a valuable
tool in understanding obesity insulin resistance relationship.
There is need to standardize the technique and overcome
the problems of lack of validation and nonreplication.
Integration of expression proﬁling with clinical phenotypes
and genotyping has potential to open avenues for its clinical
application like classiﬁcation of obesity, molecular diagnosis
and newer therapeutic options.
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